Skip to content

Serotonin: all studies

Page 356 of 401: studies 3,551 to 3,560 of 4,004, newest first. Back to the serotonin overview

Research

Transcriptomic configuration of mouse brain induced by adolescent exposure to 3,4-methylenedioxymethamphetamine.

Toxicology and Applied Pharmacology May 15, 2009 Jung Woo Eun, Seung Jun Kwack, Ji Heon Noh et al.

The amphetamine derivative (+/-)-3,4-methylenedioxymethamphetamine (MDMA or ecstasy) is a synthetic amphetamine analogue used recreationally to obtain an enhanced affiliative emotional response. MDMA is a potent monoaminergic neurotoxin with the potential to damage brain serotonin and/or dopamine neurons. As the majority of MDMA users are young adults, the risk that users may expose the fetus...

Apical regional wall motion abnormalities reminiscent to Tako-Tsubo cardiomyopathy following consumption of psychoactive fungi.

International journal of cardiology May 1, 2009 Holger M Nef, Helge Möllmann, Pirmin Hilpert et al. 24 citations

Consumption of natural hallucinogenic substances continues to be a problem. In this case we report from a young male patient presenting with an acute coronary syndrome with significant ST-elevation after the abuse of psychoactive fungi, commonly referred to as "magic mushrooms". Coronary angiography excludes relevant coronary artery disease. In ventriculography contractile dysfunction with...

Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone.

Neuroscience April 10, 2009 B N Johnson, Bryan K. Yamamoto

Exposure to stress alters the behavioral and neurochemical effects of drugs of abuse. However, it is unknown if chronic stress can affect the serotonergic depletions induced by the psychostimulant drug 3,4-methylenedioxymethamphetamine (MDMA). Rats were exposed to 10 days of chronic unpredictable stress (CUS) which resulted in the predicted elevation of basal plasma corticosterone...

Decision making as a predictor of first ecstasy use: a prospective study.

Psychopharmacology April 2009 Thelma Schilt, Anneke E. Goudriaan, Maarten W Koeter et al.

Ecstasy (+/-3,4-methylenedioxymethamphetamine) is a widely used recreational drug that may damage the serotonin system and may entail neuropsychological dysfunctions. Few studies investigated predictors for ecstasy use. Self-reported impulsivity does not predict the initiation of ecstasy use; the question is if neuropsychological indicators of impulsivity can predict first ecstasy use. This...

Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A.

Addiction Biology April 2009 Ema Alves, Teresa Summavielle, Cecília Juliana Alves et al.

The administration of a neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') to the rat results in mitochondrial oxidative damage in the central nervous system, namely lipid and protein oxidation and mitochondrial DNA deletions with subsequent impairment of the correspondent protein expression. Although these toxic effects were shown to be prevented by monoamine oxidase B...

Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI.

Psychopharmacology April 2009 Danuta Marona‐lewicka, Benjamin R Chemel, David E Nichols

Lysergic acid diethylamide (LSD) differs from other types of hallucinogens in that it possesses direct dopaminergic effects. The exact nature of this component has not been elucidated. The present study sought to characterize the effects of several dopamine D(4) agonists and antagonists on the discriminative stimulus effect of LSD at two pretreatment times and 2,5-dimethoxy-4-iodoamphetamine...

Early preclinical studies of discriminable sedative and hallucinogenic drug effects.

Psychopharmacology April 2009 Herbert Barry, James B. Appel

One important technique in behavioral pharmacology is to train laboratory animals to discriminate between a psychoactive drug effect and a nondrug condition. Tests with different drugs have identified several categories of drugs that have different discriminable effects. The two authors describe and discuss the early research on discriminable effects of sedative and hallucinogenic drugs and...

Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.

Psychopharmacology April 2009 Jerrold C Winter

Although man's first encounters with hallucinogens predate written history, it was not until the rise of the sister disciplines of organic chemistry and pharmacology in the nineteenth century that scientific studies became possible. Mescaline was the first to be isolated and its chemical structure determined. Since then, additional drugs have been recovered from their natural sources and...

Psychedelics and schizophrenia.

Trends in Neurosciences April 1, 2009 Javier González-Maeso, Stuart C. Sealfon

Research on psychedelics such as lysergic acid diethylamide (LSD) and dissociative drugs such as phencyclidine (PCP) and the symptoms, neurochemical abnormalities and treatment of schizophrenia have converged. The effects of hallucinogenic drugs resemble some of the core symptoms of schizophrenia. Some atypical antipsychotic drugs were identified by their high affinity for serotonin 5-HT(2A)...

Development of a LC–MS/MS Method to Analyze 5-Methoxy-N,N-Dimethyltryptamine and Bufotenine: Application to Pharmacokinetic Study

Bioanalysis March 27, 2009 Hong-Wu Shen, Xi-Ling Jiang, Ai-Ming Yu 26 citations

INTRODUCTION: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive indolealkylamine substance that has been used for recreational purpose and may lead to fatal toxicity. While 5-MeO-DMT is mainly inactivated via deamination, it is O-demethylated to an active metabolite, bufotenine. Quantitation of 5-MeO-DMT and bufotenine is essential to understand the exposure to and the effects of...

DOI: 10.4155/bio.09.7 (opens in new tab) Chromatography Metabolite Protein precipitation Pharmacokinetics +1